BR112012000890A2 - formas de base livre cristalina de um composto bifenil - Google Patents

formas de base livre cristalina de um composto bifenil

Info

Publication number
BR112012000890A2
BR112012000890A2 BR112012000890A BR112012000890A BR112012000890A2 BR 112012000890 A2 BR112012000890 A2 BR 112012000890A2 BR 112012000890 A BR112012000890 A BR 112012000890A BR 112012000890 A BR112012000890 A BR 112012000890A BR 112012000890 A2 BR112012000890 A2 BR 112012000890A2
Authority
BR
Brazil
Prior art keywords
free base
base forms
crystalline free
biphenyl compound
biphenyl
Prior art date
Application number
BR112012000890A
Other languages
English (en)
Inventor
Woollam Grahame
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42562758&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012000890(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of BR112012000890A2 publication Critical patent/BR112012000890A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • A61K9/124Aerosols; Foams characterised by the propellant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C07D211/64Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having an aryl radical as the second substituent in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
BR112012000890A 2009-07-15 2010-07-14 formas de base livre cristalina de um composto bifenil BR112012000890A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22580309P 2009-07-15 2009-07-15
PCT/US2010/041903 WO2011008809A1 (en) 2009-07-15 2010-07-14 Crystalline freebase forms of a biphenyl compound

Publications (1)

Publication Number Publication Date
BR112012000890A2 true BR112012000890A2 (pt) 2017-10-31

Family

ID=42562758

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012000890A BR112012000890A2 (pt) 2009-07-15 2010-07-14 formas de base livre cristalina de um composto bifenil

Country Status (21)

Country Link
US (11) US8541451B2 (pt)
EP (2) EP2453894B1 (pt)
JP (4) JP5651174B2 (pt)
KR (1) KR101742252B1 (pt)
CN (1) CN102470130B (pt)
AU (1) AU2010273514B2 (pt)
BR (1) BR112012000890A2 (pt)
CA (2) CA2765621C (pt)
DK (1) DK2453894T3 (pt)
ES (2) ES2639642T3 (pt)
HK (2) HK1168050A1 (pt)
HR (1) HRP20151344T1 (pt)
HU (1) HUE026414T2 (pt)
IL (1) IL216995A (pt)
MX (1) MX2012000682A (pt)
PL (2) PL2987490T3 (pt)
PT (1) PT2453894E (pt)
SG (2) SG178036A1 (pt)
SI (1) SI2453894T1 (pt)
SM (1) SMT201600019B (pt)
WO (1) WO2011008809A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
CA2765621C (en) 2009-07-15 2018-02-13 Theravance, Inc. Crystalline freebase forms of a biphenyl compound
SG186708A1 (en) * 2010-07-13 2013-02-28 Theravance Inc Process for preparing a biphenyl-2-ylcarbamic acid
DK2958916T3 (en) * 2013-02-21 2018-11-12 Pfizer Solid forms of a selective CDK4 / 6 inhibitor
WO2015070366A1 (en) 2013-11-12 2015-05-21 Merck Sharp & Dohme Corp. Aryl linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug
CN112694434B (zh) * 2020-12-29 2023-06-16 浙江和泽医药科技股份有限公司 一种雷芬那辛新中间体及其活性亲电砌块和雷芬那辛的新制备方法
WO2023104920A1 (en) 2021-12-09 2023-06-15 Medichem, S.A. Crystalline acetone solvate of revefenacin
CN114276290B (zh) * 2021-12-24 2024-05-28 浙江和泽医药科技股份有限公司 一种雷芬那辛无水晶型及其制备方法
CN117263849A (zh) * 2023-09-19 2023-12-22 山东京卫制药有限公司 一种雷芬那辛三水合物晶型及其制备方法
CN117263848A (zh) * 2023-09-19 2023-12-22 山东京卫制药有限公司 一种雷芬那辛的吸入喷雾剂
CN117180235A (zh) * 2023-09-19 2023-12-08 山东京卫制药有限公司 一种无定型雷芬那辛吸入制剂

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2425983C3 (de) * 1973-06-12 1978-09-14 Toyama Chemical Co. Ltd., Tokio Sulfonsäuresalze von Acylcholinen, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzung
BR8007911A (pt) 1979-12-06 1981-06-16 Glaxo Group Ltd Inalador aperfeicoado
CY1492A (en) 1981-07-08 1990-02-16 Draco Ab Powder inhalator
NO166268C (no) 1985-07-30 1991-07-03 Glaxo Group Ltd Innretning for administrering av medikamenter til pasienter.
US5225183A (en) 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
SK280968B6 (sk) 1990-03-02 2000-10-09 Glaxo Group Limited Balenie medikamentu na použite v inhalačnom prístroji
US6006745A (en) 1990-12-21 1999-12-28 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
US5874063A (en) 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
WO1992022286A1 (en) 1991-06-12 1992-12-23 Minnesota Mining And Manufacturing Company Albuterol sulfate suspension aerosol formulations
US5337740A (en) 1991-08-01 1994-08-16 New England Pharmaceuticals, Inc. Inhalation devices
EP0717987B1 (en) 1991-12-18 2001-08-29 Minnesota Mining And Manufacturing Company Suspension aerosol formulations
US5239993A (en) 1992-08-26 1993-08-31 Glaxo Inc. Dosage inhalator providing optimized compound inhalation trajectory
US5415162A (en) 1994-01-18 1995-05-16 Glaxo Inc. Multi-dose dry powder inhalation device
EP0747355A4 (en) 1994-02-10 1997-04-09 Yamanouchi Pharma Co Ltd NEW CARBAMATES AND MEDICINAL PRODUCTS CONTAINING THEM
US5983956A (en) 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
US5637820A (en) * 1995-01-06 1997-06-10 Wittman; Kenneth L. Stringed instrument with on-board tuner
SE9501384D0 (sv) 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
NZ306280A (en) 1995-04-14 1999-07-29 Glaxo Wellcome Inc Metered dose inhaler for salmeterol
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
AU9281298A (en) 1997-10-01 1999-04-23 Kyowa Hakko Kogyo Co. Ltd. Benzodioxole derivatives
EP1070056B1 (en) 1998-03-14 2004-06-30 ALTANA Pharma AG Phthalazinone pde iii/iv inhibitors
CA2328882A1 (en) 1998-04-18 1999-10-28 Glaxo Group Limited Pharmaceutical aerosol formulation
GB9808802D0 (en) 1998-04-24 1998-06-24 Glaxo Group Ltd Pharmaceutical formulations
SE9804000D0 (sv) 1998-11-23 1998-11-23 Astra Ab New composition of matter
US6693202B1 (en) * 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
WO2000061108A1 (en) 1999-04-14 2000-10-19 Glaxo Group Limited Pharmaceutical aerosol formulation
UA73965C2 (en) 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
US7144908B2 (en) 2001-03-08 2006-12-05 Glaxo Group Limited Agonists of beta-adrenoceptors
ATE381537T1 (de) 2001-03-22 2008-01-15 Glaxo Group Ltd Formanilid-derivative als beta2-adrenorezeptor- agonisten
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
PL393155A1 (pl) 2001-09-14 2011-03-28 Glaxo Group Limited Pochodne fenetanoloaminy do leczenia chorób układu oddechowego
US6653323B2 (en) 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
PE20050973A1 (es) * 2003-10-29 2005-11-19 Theravance Inc Sales de acido naftalen-1,5-disulfonico de un compuesto de 4-amino-1-(piridilmetil)piperidina como antagonistas de receptores muscarinicos
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
TW200540154A (en) * 2004-06-10 2005-12-16 Theravance Inc Crystalline form of a substituted pyrrolidine compound
TWI372749B (en) 2005-03-10 2012-09-21 Theravance Inc Crystalline forms of a biphenyl compound
US20060205949A1 (en) * 2005-03-10 2006-09-14 Theravance, Inc. Crystalline forms of a biphenyl compound
US7465870B1 (en) * 2008-03-11 2008-12-16 Homan Randy W Illuminated heart-shaped guitar with strobe lights and a modified bridge
CA2765621C (en) 2009-07-15 2018-02-13 Theravance, Inc. Crystalline freebase forms of a biphenyl compound
SG186708A1 (en) 2010-07-13 2013-02-28 Theravance Inc Process for preparing a biphenyl-2-ylcarbamic acid

Also Published As

Publication number Publication date
US20160143897A1 (en) 2016-05-26
US20220306580A1 (en) 2022-09-29
EP2987490B1 (en) 2017-06-14
CA2989129C (en) 2021-03-09
HUE026414T2 (hu) 2016-05-30
SG10201407913UA (en) 2015-01-29
PT2453894E (pt) 2016-02-02
KR20130027004A (ko) 2013-03-14
US9765028B2 (en) 2017-09-19
JP5651174B2 (ja) 2015-01-07
ES2639642T3 (es) 2017-10-27
US8921396B2 (en) 2014-12-30
HK1219415A1 (zh) 2017-04-07
US20200308116A1 (en) 2020-10-01
ES2557553T3 (es) 2016-01-27
AU2010273514A1 (en) 2012-01-19
CA2989129A1 (en) 2011-01-20
US9226896B2 (en) 2016-01-05
KR101742252B1 (ko) 2017-05-31
US20170081283A1 (en) 2017-03-23
IL216995A (en) 2017-10-31
CN102470130B (zh) 2013-09-04
CA2765621C (en) 2018-02-13
EP2453894B1 (en) 2015-11-04
US11858898B2 (en) 2024-01-02
US20130338191A1 (en) 2013-12-19
US20180186740A1 (en) 2018-07-05
JP2016026214A (ja) 2016-02-12
HRP20151344T1 (hr) 2016-01-01
SI2453894T1 (sl) 2016-02-29
US20110015163A1 (en) 2011-01-20
US9415041B2 (en) 2016-08-16
US20220009890A1 (en) 2022-01-13
SMT201600019B (it) 2016-02-25
WO2011008809A1 (en) 2011-01-20
JP2012533550A (ja) 2012-12-27
US20230303492A1 (en) 2023-09-28
MX2012000682A (es) 2012-02-28
US8541451B2 (en) 2013-09-24
AU2010273514B2 (en) 2015-01-22
US20190248743A1 (en) 2019-08-15
EP2987490A1 (en) 2016-02-24
DK2453894T3 (en) 2016-01-25
US11008289B2 (en) 2021-05-18
US10550081B2 (en) 2020-02-04
PL2453894T3 (pl) 2016-04-29
JP2015003929A (ja) 2015-01-08
PL2987490T3 (pl) 2017-12-29
EP2453894A1 (en) 2012-05-23
JP2017171692A (ja) 2017-09-28
HK1168050A1 (zh) 2012-12-21
US11691948B2 (en) 2023-07-04
US20150164796A1 (en) 2015-06-18
CA2765621A1 (en) 2011-01-20
JP6338505B2 (ja) 2018-06-06
SG178036A1 (en) 2012-03-29
US11649209B2 (en) 2023-05-16
CN102470130A (zh) 2012-05-23
IL216995A0 (en) 2012-02-29
US10100013B2 (en) 2018-10-16

Similar Documents

Publication Publication Date Title
BR112012000890A2 (pt) formas de base livre cristalina de um composto bifenil
LTPA2020505I1 (lt) Nauji tricikliniai junginiai
CY2017026I1 (el) Τετρακυκλικη ενωση
DK2662352T3 (da) Fremgangsmåde til fremstilling af phenylacetamidforbindelse
SMT201600008B (it) Composti di piridazinone
DK2262793T3 (da) Krystallinske former af nilotinib-hci
BRPI1013868A2 (pt) composto diaciletilenodiamina
BRPI1010884A2 (pt) composto inibidores hdac de alcanoilamino benzamida anilina
DK2494150T3 (da) Positioneringsværktøj
BRPI1013482A2 (pt) método para produzir um composto
BRPI1007017A2 (pt) uso de um composto.
BR112012012778A8 (pt) disposição para unir um micro componente a um substrato
CO6801790A2 (es) Marcado compuesto a base de precusores de cristales líquidos quirales
UY33156A (es) Nuevos compuestos tienopirrol
EP2483366A4 (en) DEUTERATED COMPOUNDS FOR LUMINESCENT APPLICATIONS
EP2427531A4 (en) DEUTERIZED CONNECTIONS FOR LUMINESCENCE APPLICATIONS
BRPI1010571A2 (pt) processo para a preparação de um composto útil como um inibidor de tafla.
BRPI0921210A2 (pt) processos para a preparação de compostos de arilaminas
BRPI1008308A2 (pt) processo para produzir um composto
DK3246325T3 (da) Krystaller af en 2-acylaminothiazol-forbindelse
EP2516380A4 (en) DETERIORATED COMPOUNDS FOR LUMINESCENT APPLICATIONS
BR112012009784A2 (pt) composto benzazepínico
BRPI0922920A2 (pt) formas cristalinas de um composto de 3-carboxipropil-aminotetralina
BRPI1013729A2 (pt) compostos bisazo
BRPI1014266A2 (pt) Compostos bisazo

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: THERAVANCE BIOPHARMA RANDD IP, LLC (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]